{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:30:39Z","timestamp":1767828639816,"version":"3.49.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,17]]},"abstract":"<jats:p>Due to the urgency of controlling the coronavirus disease 2019 pandemic, coronavirus disease 2019 messenger ribonucleic acid (mRNA) vaccines have been expeditiously approved and introduced in several countries without sufficient evaluation for adverse events. We analyzed adverse events among Korean healthcare workers who received all 3 doses of the BNT162b2 mRNA vaccine. This survey was conducted among hospital workers of Inha University Hospital who had received the BNT162b2 mRNA vaccine for their first, second, third rounds, and using a diary card. The surveyed adverse events included local (redness, edema, and injection site pain) and systemic (fever, fatigue, headache, chill, myalgia, arthralgia, vomiting, diarrhea, pruritis, and urticaria) side effects and were divided into 5 grades (Grade 0\u2005=\u2005none \u2013 Grade 4\u2005=\u2005critical). Based on adverse events reported at least once after any of the 3 doses, the most common systemic adverse reactions were chills and headache (respectively, 62.6%, 62.4%), followed by myalgia (55.3%), arthralgia (53.4%), fatigue (51.6%), pruritus (38.1%), and fever (36.5%). The frequency and duration of adverse events were significantly greater in women (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05) than men. Except for redness, pruritus, urticaria, and most adverse reactions had a higher rate of occurrence after the third dose in subjects who also had reactions with the second dose. However, grade 4 adverse events did occur with the third dose in some patients, even if there were no side effects with the first and second doses. Adverse events experienced with the first and second doses of the BNT162b2 mRNA vaccine in Korean healthcare workers increased the incidence of adverse events at the time of the third dose. On the other hand, grade 4 adverse events could still occur with the third dose even though there were no side effects with the first and second doses.<\/jats:p>","DOI":"10.1097\/md.0000000000033236","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T16:04:13Z","timestamp":1679069053000},"page":"e33236","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers"],"prefix":"10.1097","volume":"102","author":[{"given":"Dong Yeop","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Preventive Medicine, Ulsan University Hospital, Ulsan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Yoon","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Ulsan University Hospital, Ulsan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunjung","family":"Kim","sequence":"additional","affiliation":[{"name":"Infection Control Unit, Inha University Hospital, Incheon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-joo","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hyeon","family":"Baek","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Soo","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Youn","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Nursing, Inha University College of Medicine, Incheon, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-0221","authenticated-orcid":false,"given":"Jae Hyoung","family":"Im","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019.","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/cei.13517","article-title":"Vaccines for COVID-19.","volume":"202","author":"Tregoning","year":"2020","journal-title":"Clin Experimental Immunol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13577-021-00512-4","article-title":"COVID-19 vaccines: rapid development, implications, challenges and future prospects.","volume":"34","author":"Kashte","year":"2021","journal-title":"Hum Cell"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0140-6736(20)32623-4","article-title":"Oxford\u2013AstraZeneca COVID-19 vaccine efficacy.","volume":"397","author":"Knoll","year":"2021","journal-title":"Lancet"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMc2036242","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.","volume":"384","author":"Skowronski","year":"2021","journal-title":"N Engl J Med"},{"key":"R6-20250504","article-title":"Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows.","volume":"371","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine.","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant.","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2213-2600(21)00559-2","article-title":"Omicron variant and booster COVID-19 vaccines.","volume":"10","author":"Burki","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent Omicron-containing booster vaccine against Covid-19.","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jgg.2021.02.006","article-title":"COVID-19 mRNA vaccines.","volume":"48","author":"Huang","year":"2021","journal-title":"J Genet Genomics"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/17425247.2014.901308","article-title":"Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.","volume":"11","author":"Deering","year":"2014","journal-title":"Expert Opin Drug Deliv"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"339","DOI":"10.53854\/liim-2903-4","article-title":"A narrative review of emergency use authorization versus full FDA approval and its effect on COVID-19 vaccination hesitancy.","volume":"29","author":"Koritala","year":"2021","journal-title":"Infez Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 COVID-19 vaccine.","volume":"386","author":"Moreira","year":"2022","journal-title":"New England J Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.2147\/IJGM.S376316","article-title":"The adverse reactions of Pfizer BioNTech COVID-19 vaccine booster dose are mild and similar to the second dose responses: a retrospective cross-sectional study.","volume":"15","author":"El-Shitany","year":"2022","journal-title":"Int J Gen Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/vaccines10020233","article-title":"Gender differences in adverse events following the Pfizer-BioNTech COVID-19 vaccine.","volume":"10","author":"Green","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3201\/eid2807.212330","article-title":"Self-reported and physiologic reactions to third BNT162b2 mRNA COVID-19 (Booster) vaccine dose.","volume":"28","author":"Mofaz","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/AOG.0000000000004889","article-title":"Safety of booster doses of Coronavirus Disease 2019 (COVID-19) vaccine in pregnancy in the vaccine adverse event reporting system.","volume":"140","author":"Moro","year":"2022","journal-title":"Obstet Gynecol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:11:57Z","timestamp":1746328317000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033236","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,17]]}}}